Foresite Capital

Founded in 2011, Foresite Capital is a healthcare and life sciences investment firm based in Larkspur, California. It employs rigorous scientific and data-driven approaches to invest in promising healthcare businesses across various stages, with a focus on companies employing tools of data science and machine intelligence.

Vikram Bajaj

Managing Director

Jacob Barlow

Senior Associate

Elizabeth Liz Canis

Senior Advisor

Hyung Chun

Partner

Insiya Essani

Senior Associate

Chase Kelley

Senior Associate

Uplaksh Kumar Ph.D

Venture Partner

Dorothy Margolskee

Managing Partner

Stephen Peterson

Managing Director

Hemaka Rajapakse

Managing Director

Jonathan Robbins

Investor

Austin Nalen Sprole

Senior Associate

Hadi Tabbaa

Managing Director

Tony Wiemelt

Managing Director

Cindy Xiong Ph.D

Investor

162 past transactions

RayThera

Series A in 2025
RayThera is a biopharmaceutical company dedicated to developing innovative small molecule therapies, primarily in the field of immunology. Leveraging extensive drug discovery experience, the company aims to address critical unmet medical needs, enhancing the development process while maintaining high-quality standards.

Latigo Biotherapeutics

Series B in 2025
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Eikon Therapeutics

Series D in 2025
Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.

Abcuro

Series C in 2025
Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Ikena Oncology

Post in 2024
Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

RAPT Therapeutics

Post in 2024
RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally delivered small-molecule therapies for oncology and inflammatory diseases. It uses a proprietary discovery and development engine to create highly selective compounds that modulate immune responses. The company's lead oncology candidate, FLX475, targets the C-C motif chemokine receptor 4 and is in a Phase 1/2 program as monotherapy and in combination with pembrolizumab. The lead inflammation candidate, RPT193, is designed to selectively inhibit migration of type 2 T helper cells into inflamed tissues. Additional targets such as general control nonderepressible 2 and hematopoietic progenitor kinase 1 are in discovery. Founded in 2015 and headquartered in South San Francisco, the company aims to address unmet medical needs in cancer and inflammatory diseases.

Pleno

Series B in 2024
Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

Sollis Health

Series B in 2024
Sollis Health offers concierge urgent and emergency care with round-the-clock access to medical facilities and ER physicians who manage care from check-in through follow-up. The service suite includes advanced diagnostic imaging, VIP support from leading hospitals, and fast access to a hand-selected network of specialists, along with executive health programs and proactive preventive services to improve medical experience during acute illnesses or emergencies.

Chimagen Biosciences

Series B in 2024
Chimagen Biosciences specializes in developing a novel class of multi-functional monoclonal antibodies for cancer therapy.

Seaport Therapeutics

Series B in 2024
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

Foresight Diagnostics

Series B in 2024
Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

Spear Bio

Series A in 2024
Spear Bio is a biotechnology company based in Weston, Massachusetts, founded in 2021. The company specializes in ultrasensitive protein detection technology, which significantly enhances healthcare diagnostics. Its innovative approach enables the quantification of minute protein biomarkers from samples collected at home, facilitating self-testing and telemedicine applications. By allowing clinicians to detect these biomarkers from small sample volumes, Spear Bio's technology integrates seamlessly into existing workflows for sample collection, processing, and detection, thereby improving the overall efficiency of healthcare delivery.

Thyme Care

Series C in 2024
Thyme Care is a healthcare company specializing in oncology care management services. It offers an integrated solution for patients and providers, partnering with health plans to deliver comprehensive, personalized support to cancer patients.

Element Biosciences

Series D in 2024
Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

CASI Pharmaceuticals

Post in 2024
CASI Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and launching products in China, the United States, and globally. CASI's product portfolio includes several therapeutics, such as EVOMELA, which is used as a conditioning treatment prior to autologous stem cell transplants for multiple myeloma patients, along with CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. The company's primary revenue driver is the sales of EVOMELA, as it executes its strategy to become a leading biopharmaceutical player by leveraging its expertise in regulatory and commercial operations within the China market.

Cullinan Therapeutics

Post in 2024
Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Alumis

Series C in 2024
Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

enGene

Post in 2024
EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Latigo Biotherapeutics

Series A in 2024
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Genomics

Series C in 2024
Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Remix Therapeutics

Venture Round in 2024
Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

Thyme Care

Series B in 2023
Thyme Care is a healthcare company specializing in oncology care management services. It offers an integrated solution for patients and providers, partnering with health plans to deliver comprehensive, personalized support to cancer patients.

CG Oncology

Series F in 2023
CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies for cancer patients. It specializes in oncolytic immunotherapy, focusing on bladder cancer treatments.

Pharvaris

Post in 2023
Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Foresight Diagnostics

Series B in 2023
Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

Cerevance

Series B in 2023
Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Evonetix

Series B in 2023
Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

Galileo

Series D in 2022
Galileo is a technology company based in New York, founded in 2014, specializing in healthcare solutions. The company offers a mobile application and online communication platform that enables medical professionals to provide comprehensive clinical care directly from their phones. This includes synchronous and asynchronous telecommunications technologies for connecting providers with patients. Galileo's services cater to diverse patient populations, offering high-touch, data-driven, multi-specialty longitudinal care over the phone, at home, and in various settings. The company is recognized by regional and national health plans, employers, and Fortune 500 companies as a leading solution for improving population health.

Detect

Series C in 2022
Detect they build tools that empower people to understand their health.

Folx Health

Series B in 2022
Folx Health is a Boston-based telehealth platform founded in 2020, specializing in digital healthcare services tailored for the LGBTQIA+ community. It offers access to queer and trans clinicians, focusing on gender-affirming hormone therapy, sexual health, and family creation services.

Pleno

Series A in 2022
Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

Nested Therapeutics

Series A in 2022
Nested Therapeutics is a stealth biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company specializes in the development of precision oncology therapies aimed at targeting specific cancer genes. By identifying new driver mutations, Nested Therapeutics employs a platform that integrates insights from genomics, computational chemistry, proteomics, and artificial intelligence to discover novel small-molecule drugs. This innovative approach enables healthcare professionals to administer more effective precision medications, ultimately improving treatment outcomes for cancer patients.

MyOme

Series B in 2022
MyOme develops a genetic testing technology that provides comprehensive health insights through whole genome sequencing. Its platform offers detailed reports on disease risk and medication response, accompanied by independent physician reviews and genetic counseling. The company ensures ongoing updates using advanced technologies, empowering individuals to make informed health decisions while maintaining data privacy and security.

Remix Therapeutics

Series B in 2022
Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

Mirvie

Series B in 2022
Mirvie is a biotechnology company specializing in precise, non-invasive diagnostic tests for maternal-fetal health. Founded in 2018, the company aims to enhance pregnancy safety by providing actionable insights to families and enabling early intervention for potential complications.

Kriya Therapeutics

Series C in 2022
Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

DNAnexus

Series H in 2022
DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

TenSixteen Bio

Series A in 2022
TenSixteen Bio is a biotechnology company dedicated to developing innovative therapeutics targeting various diseases. It leverages somatic mosaicism and clonal hematopoiesis (CHIP) to discover and advance treatments for age-related disorders.

ImmPACT Bio

Series B in 2022
ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells for the treatment of solid tumors. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies that target specific gene loss features in tumor cells, allowing for the selective destruction of cancerous tissues while preserving healthy ones. This technology aims to enhance tumor specificity, enabling the CAR-T cells to induce cytotoxicity only when engaging with tumor cells, thereby minimizing the safety risks commonly associated with existing CAR-T therapies. ImmPACT Bio's innovative approach seeks to improve treatment outcomes for cancer patients by offering a more precise and safer therapeutic option.

Maze Therapeutics

Venture Round in 2022
Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific patient populations.

Velia

Series A in 2022
Velia operates a biotechnology platform designed to propel the advancement of targeted therapies. It offers extensive genomic and proteomic data analysis, sophisticated bioinformatics, and customizable research tools, empowering pharmaceutical and biotech companies to expedite drug discovery and development.

Pardes Biosciences

Post in 2021
Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections such as COVID-19. Utilizing modern reversible-covalent chemistry, the company is dedicated to discovering and developing novel oral drug candidates. Its lead product, PBI-0451, is an oral antiviral designed to treat and prevent infections caused by SARS-CoV-2, the virus responsible for COVID-19. Pardes Biosciences aims to enhance patient access to effective treatments, catering to both adult and pediatric populations, while striving to provide convenient and accessible options for those affected by life-threatening viral infections. The company is committed to contributing to global health solutions and improving patient outcomes.

Tasso

Series B in 2021
Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

Mythic Therapeutics

Series B in 2021
Mythic Therapeutics is a biotechnology company specializing in innovative cancer therapeutics. It focuses on enhancing antibody-drug conjugates (ADCs) and other antibody-based therapies using advanced protein engineering techniques, aiming to boost potency without compromising safety.

Odyssey Therapeutics

Series A in 2021
Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

bit.bio

Series B in 2021
Bit.bio specializes in applying computational principles to biology, focusing on developing a scalable platform capable of producing consistent batches of every human cell. This enables more accurate research, drug discovery, and cell therapy applications.

Mammoth Biosciences

Series D in 2021
Mammoth Biosciences harnesses diverse CRISPR systems for various applications. It offers DETECTR™ for nucleic acid detection in diseases like cancer and infections, and CRISPR-Cas systems for therapeutic genome editing in immuno-oncology, autoimmune diseases, and liver disorders. Its solutions span healthcare, agriculture, environmental monitoring, biodefense, and other sectors.

Tango Therapeutics

Post in 2021
Tango Therapeutics is a biotechnology company focused on developing cancer therapies based on the genetic principle of synthetic lethality. It aims to counteract tumor suppressor gene loss, reverse immune evasion in cancer cells, and identify effective drug combinations.

XinThera

Series B in 2021
XinThera is a drug discovery company dedicated to developing precision medicines for the treatment of cancer and immunologic diseases. The company utilizes advanced computational chemistry technologies to design small molecule therapies aimed at well-validated targets that are often considered challenging in oncology and immunology. By focusing on these promising targets, XinThera strives to provide effective drug therapies that can address unmet medical needs for patients suffering from these conditions.

Kriya Therapeutics

Series B in 2021
Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

Element Biosciences

Series C in 2021
Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

HealthVerity

Series D in 2021
HealthVerity develops a cloud-based platform that enables healthcare enterprises to discover, integrate, and manage patient data securely. Its tools empower pharmaceutical companies, hospitals, payers, and other stakeholders to harness patient insights for improved care outcomes.

23andMe

Post in 2021
Founded in 2006, 23andMe is a biotechnology company specializing in direct-to-consumer genetic testing. It offers DNA analysis services through home-based saliva collection kits, providing insights into ancestry, traits, and health risks.

Quantum SI

Post in 2021
Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Interline Therapeutics

Series A in 2021
Interline Therapeutics is a drug discovery company that maps and modulates protein communities to reveal molecular mechanisms of disease and develop precision medicines. Using genomics, proteomics, structural biology, and computational chemistry, it analyzes signaling networks to identify genetically validated targets and design therapies that comprehensively correct dysfunctional protein communities. The company is based in South San Francisco and was established in 2020.

Aetion

Series C in 2021
Aetion is a New York‑based company that builds a real‑world evidence platform. It aggregates claims, electronic health records, registries and clinical trial data to generate analytics that help payers, providers, biopharma and medical device firms assess the effectiveness and value of treatments. The platform’s rapid‑cycle analytics enable real‑time collaboration between payers, providers and life‑science companies, supporting value‑based care decisions. Founded in 2012 by Harvard Medical School faculty and data scientists, it has partnerships with McKesson and receives backing from major venture investors. The platform is used worldwide by health‑economists, epidemiologists and biostatisticians for database analytics and comparative‑effectiveness research.

Eikon Therapeutics

Series A in 2021
Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.

Alumis

Series A in 2021
Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

Tesseract Health

Series B in 2021
Identifeye is creating prediction models that combine multiple retinal imaging modalities with expert annotations to create comprehensive and non-invasive health assessments. Identifeye Health is a part of the 4Catalyzer accelerator, which is dedicated to improving patient care globally. It has offices in Guilford, Connecticut, New York City, and Palo Alto, California.

Invivyd

Series C in 2021
Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Theseus Pharmaceuticals

Series B in 2021
Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients through the development of targeted therapies. The company focuses on discovering and commercializing innovative treatments that specifically address drug resistance mutations in critical driver oncogenes, which are genes that, when mutated, contribute to cancer progression. By leveraging advanced technology, Theseus Pharmaceuticals aims to transform cancer care and improve patient outcomes.

Inscripta

Series E in 2021
Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Crossover Health

Series D in 2021
Crossover Health designs and delivers workplace healthcare services for employers and employees, offering primary care and a broad range of ancillary and advanced services, including urgent and preventive care, chronic disease management, health risk assessment, health education, coaching, biometrics, physical therapy, chiropractic, acupuncture, care coordination, health analytics, and remote care. It operates as a primary care medical group that blends health management services with technology-enabled tools to create a comprehensive employee care experience. Founded in 2010 and based in California, Crossover Health serves client organizations through on-site and partner health centers across Silicon Valley and other U.S. locations, with a focus on improving access to care, enhancing member experience, and reducing healthcare costs for employers and their workforce.

Interline Therapeutics

Seed Round in 2021
Interline Therapeutics is a drug discovery company that maps and modulates protein communities to reveal molecular mechanisms of disease and develop precision medicines. Using genomics, proteomics, structural biology, and computational chemistry, it analyzes signaling networks to identify genetically validated targets and design therapies that comprehensively correct dysfunctional protein communities. The company is based in South San Francisco and was established in 2020.

insitro

Series C in 2021
Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Genomics

Venture Round in 2021
Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Gemini Therapeutics

Post in 2021
Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.

Delfi Diagnostics

Series A in 2021
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

Affinivax

Series C in 2021
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Kira Pharmaceuticals

Series B in 2021
Kira Pharmaceuticals, established in 2017 and headquartered in Suzhou, China, is a biotechnology company focused on developing innovative therapies targeting the complement system to treat immune-mediated diseases.

LifeMine Therapeutics

Series B in 2021
LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Cullinan Therapeutics

Series C in 2020
Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Remix Therapeutics

Series A in 2020
Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

EverlyWell

Series D in 2020
EverlyWell develops do-it-yourself kits for a vast range of at-home regulatory-compliant diagnostic tests including food sensitivity, fertility, hormones, STDs, thyroid, and metabolism among the others, allowing users to perform tests at home and receive physician-reviewed results and insights on their mobile devices. EverlyWell also provides at-home covid testing.

SomaLogic

Series A in 2020
Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.

Pharvaris

Series C in 2020
Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Decibel Therapeutics

Series D in 2020
Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Mammoth Biosciences

Series C in 2020
Mammoth Biosciences harnesses diverse CRISPR systems for various applications. It offers DETECTR™ for nucleic acid detection in diseases like cancer and infections, and CRISPR-Cas systems for therapeutic genome editing in immuno-oncology, autoimmune diseases, and liver disorders. Its solutions span healthcare, agriculture, environmental monitoring, biodefense, and other sectors.

Sestina Bio

Seed Round in 2020
Founded in 2020, Sestina Bio is a biotechnology company dedicated to developing innovative synthetic biology platforms. The company aims to tackle global challenges by integrating advanced technologies such as synthetic biology, data sciences, and bio-analytical systems.

Olema Oncology

Series C in 2020
Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Olema Oncology

Series B in 2020
Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Tasso

Series A in 2020
Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

bit.bio

Series A in 2020
Bit.bio specializes in applying computational principles to biology, focusing on developing a scalable platform capable of producing consistent batches of every human cell. This enables more accurate research, drug discovery, and cell therapy applications.

Cue

Series C in 2020
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

DNAnexus

Series G in 2020
DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Fulcrum Therapeutics

Post in 2020
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

Detect

Series B in 2020
Detect they build tools that empower people to understand their health.

insitro

Series B in 2020
Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Mindstrong

Series C in 2020
Mindstrong Health, established in 2013 and based in Mountain View, California, specializes in remote mental health care. It offers a digital therapeutic platform that combines AI-powered technology, data, and clinical expertise to monitor and improve users' mental health. The platform tracks symptoms continuously through passive data collection from human-computer interactions, enabling evidence-based interventions and personalized support. Services include cognitive behavioral therapy, psychoeducation, crisis management, and more, helping thousands of users, including those with serious mental illness.

Kriya Therapeutics

Series A in 2020
Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

Cerevance

Series B in 2020
Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Nurix Therapeutics

Venture Round in 2020
Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecule therapies aimed at modulating cellular protein levels for the treatment of cancer and immune disorders. The company has developed an integrated discovery platform known as DELigase, which leverages its expertise in E3 ligases—enzymes capable of modulating proteins within cells. Nurix's pipeline includes promising candidates such as NX-2127, an orally available Bruton’s tyrosine kinase degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, an orally available inhibitor of Casitas B-lineage lymphoma proto-oncogene B, intended for immuno-oncology applications. Founded in 2009 and headquartered in San Francisco, California, Nurix Therapeutics was formerly known as Nurix Inc. and rebranded in October 2018. The company has established strategic collaborations with major industry players, enhancing its research and development capabilities.

Vaxcyte

Series D in 2020
Vaxcyte is a biotechnology company developing vaccines to prevent or treat infectious diseases worldwide. Its lead product is VAX-24, a 24-valent pneumococcal conjugate vaccine candidate. The company also develops vaccines targeting emerging strains of pneumococcal disease (VAX-XP), Group A Strep infections (VAX-A1), and periodontal disease (VAX-PG).

Keros Therapeutics

Series C in 2020
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, dedicated to the discovery, development, and commercialization of innovative treatments for hematological and musculoskeletal disorders with significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule aimed at treating anemia and fibrodysplasia ossificans progressiva, which is currently in Phase 1 clinical trials. Another candidate, KER-012, is being explored for its potential in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Keros Therapeutics emphasizes understanding the role of the Transforming Growth Factor-Beta family of proteins, which are crucial for the regulation of blood cell production and the maintenance of muscle and bone health.

Evonetix

Series B in 2020
Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

ALX Oncology

Series C in 2020
ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Generation Bio

Series C in 2020
Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

PACT Pharma

Series C in 2020
PACT Pharma, Inc. is a biotechnology company focused on developing personalized cell-based therapies for cancer treatment. The company specializes in neoantigen-specific adoptive T-cell therapies aimed at solid tumors. Its innovative platform utilizes bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying candidate neoantigen peptides that stimulate robust antitumor T-cell responses. By pinpointing neo-epitopes unique to each patient's cancer, PACT Pharma enables the engineering of autologous T cells that specifically target and eradicate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is dedicated to advancing personalized medicine in oncology.

Element Biosciences

Series B in 2020
Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Kinnate Biopharma

Series B in 2019
Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.